臨床薬剤学

研究成果

年別の研究成果 1997 2000 2001 2002 2005 2006 2008 2009 2011 2012 2013 2017 2018 2019 2020 2021

• 82 Article
• 6 Review article
• 1 Chapter
• 1 Short survey

年別の研究成果

年別の研究成果

検索結果

• 2006

  Effects of methylenetetrahydrofolate reductase and reduced folate carrier 1 polymorphisms on high-dose methotrexate-induced toxicities in children with acute lymphoblastic leukemia or lymphoma

  Shimasaki, N., Mori, T., Samejima, H., Sato, R., Shimada, H., Yahagi, N., Torii, C., Yoshihara, H., Tanigawara, Y., Takahashi, T. & Kosaki, K., 2006 2月 1, In: Journal of Pediatric Hematology/Oncology. 28, 2, p. 64-68 5 p.

  研究成果: Article › 査読

  • Reduced Folate Carrier Protein 100%
  • Methylenetetrahydrofolate Reductase (NADPH2) 79%
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma 60%
  • Methotrexate 59%
  • Child 26%
  86 被引用数 (Scopus)

• Linear pharmacokinetics of micafungin and its active metabolites in Japanese pediatric patients with fungal infections

  Tabata, K., Katashima, M., Kawamura, A., Tanigawara, Y. & Sunagawa, K., 2006, In: Biological and Pharmaceutical Bulletin. 29, 8, p. 1706-1711 6 p.

  研究成果: Article › 査読

  • Micafungin 100%
  • Mycoses 53%
  • Pharmacokinetics 39%
  • Metabolite 37%
  • Pediatrics 33%
  30 被引用数 (Scopus)

• Novel application of proteinchip technology exploring acute rejection markers of rat small bowel transplantation

  Yamayoshi, Y., Watanabe, T., Tanabe, M., Hoshino, K., Matsumoto, K., Morikawa, Y., Shimadzu, M., Kitajima, M. & Tanigawara, Y., 2006 8月 18, In: Transplantation. 82, 3, p. 320-326 7 p.

  研究成果: Article › 査読

  • Protein Array Analysis 100%
  • Allografts 69%
  • Transplantation 60%
  • Technology 51%
  • Muramidase 38%
  9 被引用数 (Scopus)

• Phase I/II study of oxaliplatin with weekly bolus fluorouracil and high-dose leucovorin (ROX) As first-line therapy for patients with colorectal cancer

  Yamada, Y., Ohtsu, A., Boku, N., Miyata, Y., Shimada, Y., Doi, T., Muro, K., Muto, M., Hamaguchi, T., Mera, K., Yano, T., Tanigawara, Y. & Shirao, K., 2006 4月, In: Japanese journal of clinical oncology. 36, 4, p. 218-223 6 p.

  研究成果: Article › 査読

  • Leucovorin 100%
  • Oxaliplatin 98%
  • Fluorouracil 79%
  • Colorectal Neoplasms 66%
  • Neutropenia 16%
  9 被引用数 (Scopus)

• Phase I and pharmacokinetic study of edotecarin, a novel topoisomerase I inhibitor, administered once every 3 weeks in patients with solid tumors

  Yamada, Y., Tamura, T., Yamamoto, N., Shimoyama, T., Ueda, Y., Murakami, H., Kusaba, H., Kamiya, Y., Saka, H., Tanigawara, Y., McGovren, J. P. & Natsumeda, Y., 2006 8月, In: Cancer Chemotherapy and Pharmacology. 58, 2, p. 173-182 10 p.

  研究成果: Article › 査読

  • edotecarin 100%
  • EC 5.99.1.2 (DNA Topoisomerase) Inhibitor 71%
  • Topoisomerase I Inhibitors 67%
  • Dose 35%
  • Pharmacokinetics 35%
  21 被引用数 (Scopus)
• 2005

  Comprehensive screening of the thiopurine methyltransferase polymorphisms by denaturing high-performance liquid chromatography

  Udaka, T., Torii, C., Takahashi, D., Mori, T., Aramaki, M., Kosaki, R., Tanigawara, Y., Takahashi, T. & Kosaki, K., 2005 6月 1, In: Genetic Testing. 9, 2, p. 85-92 8 p.

  研究成果: Article › 査読

  • thiopurine methyltransferase 100%
  • High Pressure Liquid Chromatography 53%
  • Bone Marrow Failure Disorders 35%
  • Mercaptopurine 34%
  • azathiopurine 25%
  7 被引用数 (Scopus)

• How tightly can a drug be bound to a protein and still be removable by charcoal hemoperfusion in overdose cases?

  Kawasaki, C. I., Nishi, R., Uekihara, S., Hayano, S., Kragh-Hansen, U. & Otagiri, M., 2005, In: Journal of Toxicology - Clinical Toxicology. 43, 2, p. 95-99 5 p.

  研究成果: Article › 査読

  • Hemoperfusion 100%
  • Charcoal 87%
  • Drug 37%
  • Protein Binding 30%
  • Pharmaceutical Preparations 29%
  14 被引用数 (Scopus)

• Population pharmacokinetics of faropenem in healthy human volunteers and patients

  Hirooka, H., Sou, M., Miyata, K., Shiba, K. & Tanigawara, Y., 2005 7月, In: Japanese Journal of Clinical Pharmacology and Therapeutics. 36, 4, p. 197-207 11 p.

  研究成果: Article › 査読

  • fropenem 100%
  • Pharmacokinetics 41%
  • Healthy Volunteers 36%
  • Population 21%
  • Creatinine 10%
  1 被引用数 (Scopus)
• 2004

  A major influence of CYP2C19 genotype on the steady-state concentration of N-desmethylclobazam

  Kosaki, K., Tamura, K., Sato, R., Samejima, H., Tanigawara, Y. & Takahashi, T., 2004 12月, In: Brain and Development. 26, 8, p. 530-534 5 p.

  研究成果: Article › 査読

  • N-desmethylclobazam 100%
  • Clobazam 80%
  • Cytochrome P-450 CYP2C19 67%
  • Genotype 36%
  • Cytochrome P-450 CYP3A Inducers 18%
  68 被引用数 (Scopus)

• Genetic Polymorphisms and Individual Variability in Drug Response

  Yamayoshi, Y., Mihara, K. & Tanigawara, Y., 2004 3月 1, In: Respiration and Circulation. 52, 3, p. 293-300 8 p.

  研究成果: Article › 査読
• 2003

  Actual use of anti-MRSA drugs in Japan with the focus on arbekacin

  Shimizu, K., Aikawa, N., Tanigawara, Y., Kaku, M., Imae, M., Nishizawa, N. & Nakamura, H., 2003 11月, In: Japanese Journal of Chemotherapy. 51, 11, p. 717-730 14 p.

  研究成果: Article › 査読

  • arbekacin 100%
  • Methicillin-Resistant Staphylococcus aureus 61%
  • Japan 49%
  • Teicoplanin 40%
  • Vancomycin 31%
  6 被引用数 (Scopus)

• Population Pharmacokinetics of an Angiotensin II Receptor Antagonist, Telmisartan, in Healthy Volunteers and Hypertensive Patients

  Tatami, S., Sarashina, A., Yamamura, N., Igarashi, T. & Tanigawara, Y., 2003 2月 1, In: Drug Metabolism And Pharmacokinetics. 18, 3, p. 203-211 9 p.

  研究成果: Article › 査読

  • Telmisartan 100%
  • Hypertensive 88%
  • Angiotensin II 81%
  • CL/F 75%
  • Angiotensin Receptor Antagonists 72%
  15 被引用数 (Scopus)
• 2002

  Effects of 12 Ca²⁺ antagonists on multidrug resistance, MDR1-mediated transport and MDR1 mRNA expression

  Takara, K., Sakaeda, T., Tanigawara, Y., Nishiguchi, K., Ohmoto, N., Horinouchi, M., Komada, F., Ohnishi, N., Yokoyama, T. & Okumura, K., 2002, In: European Journal of Pharmaceutical Sciences. 16, 3, p. 159-165 7 p.

  研究成果: Article › 査読

  • Barnidipine 100%
  • mepirodipine 90%
  • Verapamil 62%
  • Multiple Drug Resistance 50%
  • Antagonist 44%
  52 被引用数 (Scopus)

• Interaction of digoxin with antihypertensive drugs via MDR1

  Takara, K., Kakumoto, M., Tanigawara, Y., Funakoshi, J., Sakaeda, T. & Okumura, K., 2002 2月 15, In: Life Sciences. 70, 13, p. 1491-1500 10 p.

  研究成果: Article › 査読

  • Digoxin 100%
  • Antihypertensive 83%
  • Antihypertensive Agents 64%
  • Transcytosis 47%
  • Drug 37%
  50 被引用数 (Scopus)

• MDR1-mediated interaction of digoxin with antiarrhythmic or antianginal drugs

  Kakumoto, M., Takara, K., Sakaeda, T., Tanigawara, Y., Kita, T. & Okumura, K., 2002 12月, In: Biological and Pharmaceutical Bulletin. 25, 12, p. 1604-1607 4 p.

  研究成果: Article › 査読

  • Antianginal 100%
  • Digoxin 79%
  • Antiarrhythmic Agent 77%
  • Anti-Arrhythmia Agents 64%
  • Amiodarone 54%
  42 被引用数 (Scopus)

• N-acetyltransferase 2 genotype-related sulfapyridine acetylation and its adverse events

  Tanigawara, Y., Kita, T., Aoyama, N., Gobara, M., Komada, F., Sakai, T., Kasuga, M., Hatanaka, H., Sakaeda, T. & Okumura, K., 2002 8月, In: Biological and Pharmaceutical Bulletin. 25, 8, p. 1058-1062 5 p.

  研究成果: Article › 査読

  • Sulfapyridine 100%
  • Acetyltransferases 79%
  • Acetylation 64%
  • N-acetylsulfapyridine 62%
  • Genotype 44%
  36 被引用数 (Scopus)

• Simvastatin and lovastatin, but not pravastatin, interact with MDR1

  Sakaeda, T., Takara, K., Kakumoto, M., Ohmoto, N., Nakamura, T., Iwaki, K., Tanigawara, Y. & Okumura, K., 2002, In: Journal of Pharmacy and Pharmacology. 54, 3, p. 419-423 5 p.

  研究成果: Article › 査読

  • Pravastatin 100%
  • Lovastatin 93%
  • Simvastatin 89%
  • Digoxin 86%
  • 3-hydroxy-3-methylglutaryl-coenzyme A 53%
  44 被引用数 (Scopus)
• 2001

  Application of population pharmacokinetic approach to clinical evaluation of anticancer agents

  Tanigawara, Y., 2001 5月, In: Gan to kagaku ryoho. Cancer & chemotherapy. 28, 5, p. 711-721 11 p.

  研究成果: Article › 査読

  • Antineoplastic Agents 100%
  • Pharmacokinetics 78%
  • Population 40%
  • Health Services Needs and Demand 16%
  • Drug Development 14%
  2 被引用数 (Scopus)

• CYP2C19 genotype related effect of omeprazole on intragastric pH and antimicrobial stability

  Kita, T., Tanigawara, Y., Aoyama, N., Hohda, T., Saijoh, Y., Komada, F., Sakaeda, T., Okumura, K., Sakai, T. & Kasuga, M., 2001, In: Pharmaceutical research. 18, 5, p. 615-621 7 p.

  研究成果: Article › 査読

  • Intragastric 100%
  • Omeprazole 94%
  • Cytochrome P-450 CYP2C19 87%
  • Genotype 47%
  • Antimicrobial Agent 46%
  47 被引用数 (Scopus)

• Dose-finding phase I study of simultaneous weekly infusion with doxorubicin and docetaxel in patients with advanced breast cancer

  Ito, Y., Aiba, K., Horikoshi, N., Saotome, T., Irie, T., Sugiyama, K., Nakane, M., Hashimoto, D., Yoshida, N., Mizunuma, N., Takahashi, S. & Tanigawara, Y., 2001 1月 1, In: International Journal of Clinical Oncology. 6, 5, p. 242-247 6 p.

  研究成果: Article › 査読

  • Docetaxel 100%
  • Doxorubicin 82%
  • Breast Neoplasms 57%
  • Asthenia 14%
  • Febrile Neutropenia 13%
  4 被引用数 (Scopus)

• Factors influencing the prediction of steady state concentrations of digoxin

  Nakamura, T., Kakumoto, M., Yamashita, K., Takara, K., Tanigawara, Y., Sakaeda, T. & Okumura, K., 2001, In: Biological and Pharmaceutical Bulletin. 24, 4, p. 403-408 6 p.

  研究成果: Article › 査読

  • Digoxin 100%
  • Bayes Theorem 32%
  • verapamil drug combination quinidine 30%
  • ATP Binding Cassette Transporter, Subfamily B, Member 1 28%
  • Serum 28%
  15 被引用数 (Scopus)

• Influence of sugar chain on fibrin affinity of recombinant t-PA

  Aoki, S., Shimizu, N., Shimonishi, M., Kitagawa, M., Okumura, K. & Tanigawara, Y., 2001, In: Biological and Pharmaceutical Bulletin. 24, 3, p. 295-298 4 p.

  研究成果: Article › 査読

  • Fibrin 100%
  • Tissue Plasminogen Activator 88%
  • Sugars 80%
  • Steric Hindrance 39%
  • hexanoic acid 14%
  3 被引用数 (Scopus)
• 2000

  Comparison of the pharmaceutical properties of sustained-release gel beads prepared by alginate having different molecular size with commercial sustained-release tablet

  Imai, T., Kawasaki, C., Nishiyama, T. & Otagiri, M., 2000 4月 27, In: Pharmazie. 55, 3, p. 218-222 5 p.

  研究成果: Article › 査読

  • Pindolol 100%
  • Alginates 75%
  • Molecular Size 68%
  • Alginate 66%
  • Tablets 59%
  24 被引用数 (Scopus)

• Nicardipine and itraconazole inhibited transcellular transport of digoxin

  Takara, K., Tanigawara, Y., Komada, F., Nishiguchi, K., Sakaeda, T. & Okumura, K., 2000 4月, In: Pharmacy and Pharmacology Communications. 6, 4, p. 167-171 5 p.

  研究成果: Article › 査読

  • Nicardipine 100%
  • Itraconazole 92%
  • Digoxin 88%
  • Transcytosis 83%
  • LLC-PK1 Cells 65%
  8 被引用数 (Scopus)

• Role of P-glycoprotein in drug disposition

  Tanigawara, Y., 2000 2月 16, In: Therapeutic Drug Monitoring. 22, 1, p. 137-140 4 p.

  研究成果: Article › 査読

  • ATP Binding Cassette Transporter, Subfamily B, Member 1 100%
  • Pharmaceutical Preparations 37%
  • Brain 33%
  • Digoxin 26%
  • Kidney 18%
  199 被引用数 (Scopus)

• The novel anticancer drug KRN5500 interacts with, but is hardly transported by, human P-glycoprotein

  Takara, K., Tanigawara, Y., Komada, F., Nishiguchi, K., Sakaeda, T. & Okumura, K., 2000 2月, In: Japanese Journal of Cancer Research. 91, 2, p. 248-254 7 p.

  研究成果: Article › 査読

  • KRN 5500 100%
  • ATP Binding Cassette Transporter, Subfamily B, Member 1 51%
  • LLC-PK1 Cells 25%
  • azidopine 21%
  • Pharmaceutical Preparations 19%
  3 被引用数 (Scopus)
• 1999

  Cellular pharmacokinetic aspects of reversal effect of itraconazole on P-glycoprotein-mediated resistance of anticancer drugs

  Takara, K., Tanigawara, Y., Komada, F., Nishiguchi, K., Sakaeda, T. & Okumura, K., 1999 12月, In: Biological and Pharmaceutical Bulletin. 22, 12, p. 1355-1359 5 p.

  研究成果: Article › 査読

  Open Access

  • Itraconazole 100%
  • ATP Binding Cassette Transporter, Subfamily B, Member 1 74%
  • Drug Resistance 61%
  • Daunorubicin 54%
  • Pharmacokinetics 50%
  57 被引用数 (Scopus)

• Effect of its demethylated metabolite on the: Pharmacokinetics of unchanged TAK-603, a new antirheumatic agent, in rats

  Tagawa, Y., Miwa, K., Tsukuda, R., Yoshimura, Y., Tanayama, S. & Tanigawara, Y., 1999 4月 24, In: Drug Metabolism and Disposition. 27, 4, p. 495-501 7 p.

  研究成果: Article › 査読

  • TAK 603 100%
  • Antirheumatic Agent 69%
  • Antirheumatic Agents 52%
  • Clearance 47%
  • Pharmacokinetics 33%
  2 被引用数 (Scopus)

• Effects of secretable SOD delivered by genetically modified cells on xanthine/xanthine oxidase and paraquat-induced cytotoxicity in vitro

  Komada, F., Nishiguchi, K., Tanigawara, Y., Iwakawa, S. & Okumura, K., 1999 8月, In: Biological and Pharmaceutical Bulletin. 22, 8, p. 846-853 8 p.

  研究成果: Article › 査読

  Open Access

  • Paraquat 100%
  • Xanthine 98%
  • Xanthine Oxidase 92%
  • Superoxide 74%
  • Superoxide Dismutase 69%
  14 被引用数 (Scopus)
• 1998

  Effects of Cu, Zn-superoxide dismutase delivered by genetically modified skin fibroblasts on cold-induced skin edema in rats

  Nishiguchi, K., Komada, F., Tanigawara, Y., Sakai, Y., Iwakawa, S. & Okumura, K., 1998 1月 1, In: Biological and Pharmaceutical Bulletin. 21, 12, p. 1379-1381 3 p.

  研究成果: Article › 査読

  Open Access

  • Evans Blue 100%
  • Superoxide Dismutase-1 80%
  • Superoxide 62%
  • Cold Temperature 57%
  • Edema 51%
  3 被引用数 (Scopus)

• Inhibitory effects of a cyclosporin derivative, SDZ PSC 833, on transport of doxorubicin and vinblastine via human P-glycoprotein

  Kusunoki, N., Takara, K., Tanigawara, Y., Yamauchi, A., Ueda, K., Komada, F., Ku, Y., Kuroda, Y., Saitoh, Y. & Okumura, K., 1998, In: Japanese Journal of Cancer Research. 89, 11, p. 1220-1228 9 p.

  研究成果: Article › 査読

  • valspodar 100%
  • Vinblastine 75%
  • ATP Binding Cassette Transporter, Subfamily B, Member 1 68%
  • Cyclosporine 58%
  • Doxorubicin 57%
  50 被引用数 (Scopus)
• 1997

  Preparation and evaluation of a suppository dosage form containing omeprazole

  Kawasaki, C., Nishi, R. & Otagiri, M., 1997 12月 1, In: Pharmaceutical Sciences. 3, 9, p. 431-434 4 p.

  研究成果: Article › 査読

  • Suppository 100%
  • Omeprazole 91%
  • Suppositories 85%
  • Dosage Forms 72%
  • Dosage Form 65%